These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22497712)

  • 21. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.
    Mackenzie IR; Neumann M; Cairns NJ; Munoz DG; Isaacs AM
    J Mol Neurosci; 2011 Nov; 45(3):402-8. PubMed ID: 21603977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct pathological subtypes of FTLD-FUS.
    Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
    Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TDP-43 and FUS: a nuclear affair.
    Dormann D; Haass C
    Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD).
    Lourenco GF; Janitz M; Huang Y; Halliday GM
    Neurobiol Dis; 2015 Oct; 82():445-454. PubMed ID: 26220395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O-GlcNAc glycosylation stoichiometry of the FET protein family: only EWS is glycosylated with a high stoichiometry.
    Kamemura K
    Biosci Biotechnol Biochem; 2017 Mar; 81(3):541-546. PubMed ID: 27903134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies.
    Koga S; Murakami A; Soto-Beasley AI; Walton RL; Baker MC; Castanedes-Casey M; Josephs KA; Ross OA; Dickson DW
    Acta Neuropathol Commun; 2023 Jul; 11(1):109. PubMed ID: 37415197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontotemporal lobar degeneration: diversity of FTLD lesions.
    Seilhean D; Bielle F; Plu I; Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What's in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?
    Menon R; Baborie A; Jaros E; Mann DM; Ray PS; Larner AJ
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1412-4. PubMed ID: 21084263
    [No Abstract]   [Full Text] [Related]  

  • 34. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
    Baloh RH
    Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of glucose hypometabolism can help differentiate FTLD-FET from other types of FTLD.
    Garcia-Guaqueta DP; Ghayal NB; Lowe VJ; Dickson DW; Whitwell JL; Josephs KA
    J Neurol; 2024 Sep; 271(9):6264-6273. PubMed ID: 39088063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain.
    Aoki N; Higashi S; Kawakami I; Kobayashi Z; Hosokawa M; Katsuse O; Togo T; Hirayasu Y; Akiyama H
    Acta Neuropathol; 2012 Sep; 124(3):383-94. PubMed ID: 22526020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical FTLD-FUS associated with ALS-TDP: a case report.
    Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
    Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
    Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
    Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
    [No Abstract]   [Full Text] [Related]  

  • 39. Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions.
    Hartikainen PH; Pikkarainen M; Hänninen T; Soininen H; Alafuzoff I
    Neuropathology; 2012 Feb; 32(1):60-8. PubMed ID: 21518013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.
    Luty AA; Kwok JB; Dobson-Stone C; Loy CT; Coupland KG; Karlström H; Sobow T; Tchorzewska J; Maruszak A; Barcikowska M; Panegyres PK; Zekanowski C; Brooks WS; Williams KL; Blair IP; Mather KA; Sachdev PS; Halliday GM; Schofield PR
    Ann Neurol; 2010 Nov; 68(5):639-49. PubMed ID: 21031579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.